AbbVie, Teva Escape Class in Generic Niaspan Pay-to-Delay Case

Aug. 18, 2021, 5:03 PM

A propose class of pension funds and other “end payers” failed to convince a Pennsylvania judge to certify their case against AbbVie Inc. and Teva Pharmaceutical Industries Ltd. for allegedly conspiring to keep a generic version of the cholesterol drug Niaspan off the market.

The plaintiffs—which include pension funds, employers, and uninsured patients— didn’t provide a reliable mechanism to distinguish between class members and intermediary drug transactions that are excluded from the class, Judge Jan E. DuBois said in a Tuesday memorandum denying class certification.

The multidistrict lawsuit, consolidated in the U.S. District Court for the Eastern District of Pennsylvania, ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.